Compare VanEck Vietnam ETF (VNM) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Vietnam ETF vs State Street SPDR S&P Biotech ETF — how do they compare? VanEck Vietnam ETF trades at $16.92, while State Street SPDR S&P Biotech ETF trades at $154.38. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, VanEck Vietnam ETF nearer its low. Which is the better fit depends on your goals.
| VNM | XBI | |
|---|---|---|
Sector | Sector/Thematic | Broad Market / Factor |
52-Week High | $19.80 | $164.28 |
52-Week Low | $15.35 | $85.16 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VNM trades at $16.84, down 2.88% on the day, reflecting a bearish technical trend with moving averages signaling strong selling pressure. The stock's current price is at a key support level of $17, with oversold RSI readings suggesting potential for a near-term bounce. Recent news highlights challenges including underperformance relative to other emerging markets and strain on Vietnam's power grid due to extreme weather.
The outlook remains cautious due to macroeconomic headwinds and geopolitical risks affecting Vietnam's market. Investment opportunity hinges on potential foreign institutional inflows following FTSE Russell's EM reclassification in September 2026. Key risks include sustained underperformance, regional instability, and domestic infrastructure pressures.
XBI trades at $150.94, down 2.14% today, with technical indicators showing a bearish trend but oversold RSI suggesting potential near-term support. The ETF lacks traditional valuation metrics due to its structure, but recent news highlights strong biotech sector momentum, including a 17% monthly gain and robust M&A activity. Analyst coverage is limited to a single hold rating, reflecting cautious optimism amid sector volatility.
Outlook: Biotech sector tailwinds from M&A and AI-driven drug discovery offer upside, but high volatility and policy risks persist. Investors should weigh XBI's equal-weight exposure to small/mid-cap biotech against its elevated beta, with technical support near $149 critical for short-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Vietnam ETF
VNM is the first and largest U.S.-listed ETF providing targeted exposure to the Vietnamese equity market. It tracks the MarketVector™ Vietnam Local Index, which includes publicly traded companies that are locally incorporated in Vietnam. It serves as a liquid, transparent vehicle for investors looking to participate in Vietnam's transition into a global manufacturing hub and its long-term potential for emerging market reclassification.
Read more on VNM →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
